CD4 and cancer: Surprisingly, the BRM binding was not observed on the PD-L1 promoter in CD4+ T cells co-cultured with cancer cells, with exception that we found enhanced recruitment of BRM +441 bp downstream of TSS (Figure 6A), although the binding at this position was labile and likely dependent on the exhaustion efficacy.